Profile
ALVOW ZTS TAK HLN TEVA NBIX
Company Name Alvotech Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $254.69M $52.30B $45.81B $43.16B $34.52B $15.32B
Employees 1.01K 13.80K 49.28K 24.56K 37.00K 1.80K
CEO Vilhelm Robert Wessman Kristin C. Peck Christophe Weber Brian James McNamara Richard D. Francis Kyle W. Gano
Ratings
ALVOW ZTS TAK HLN TEVA NBIX
Quant Rating Score 2 4 3 3 3 3
Quant Rating Sell Buy Neutral Neutral Neutral Neutral
Trading
ALVOW ZTS TAK HLN TEVA NBIX
Last Close $0.7821 $118.8 $14.14 $9.68 $24.59 $143.56
High 52 $3.84 $178.71 $15.52 $11.41 $25.83 $154.8
Low 52 $0.62 $118.8 $12.89 $8.73 $12.82 $87.59
Price vs. 52 Week High -79.63 % -33.52 % -8.89 % -15.16 % -4.8 % -7.26 %
Price vs. 52 Week Low 26.15 % 0 % 9.7 % 10.88 % 91.81 % 63.9 %
Total Return
ALVOW ZTS TAK HLN TEVA NBIX
1 Month Return -54.26 % -17.53 % 0.71 % 2.11 % 27.34 % 2.48 %
3 Month Return -37.43 % -21.96 % -6.73 % -0.05 % 36.16 % 7.83 %
6 Month Return -60.1 % -27.13 % 0.21 % -10.37 % 45.16 % 18.63 %
9 Month Return -68.08 % -24.08 % 1.73 % -3.1 % 48.4 % 25.96 %
YTD Return -74.85 % -27.09 % 6.8 % 1.47 % 11.57 % 5.17 %
1 Year Return -76.72 % -32.33 % 3.82 % 2.11 % 46.28 % 20.51 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ALVOW ZTS TAK HLN TEVA NBIX
Dividend Yield Percentage (TTM) - 1.69 % 4.41 % 1.56 % - -
Dividend Paid and Capex Coverage Ration (TTM) -0.44 % 1.89 % 2.01 % 2.01 % 2.78 % 14.57 %
Dividend Per Share (TTM) - 2 % 198 % 0.06 % - -
Payout Ratio (TTM) - 32.55 % 226.17 % 27.27 % - -
Growth
ALVOW ZTS TAK HLN TEVA NBIX
Asset Growth 28.56 % 0.76 % -9.55 % 14.37 %
Gross Profit Growth 538.44 % -0.19 % 5.47 % 25.65 %
Revenue Growth 435.56 % -0.61 % 4.41 % 24.81 %
Revenue 3 Year 55.32 % 19.01 % 1.52 % 95.79 %
Revenue 5 Year 1295.18 % 33.95 % -5.5 % 172.74 %
Revenue 10 Year 1295.18 % 33.95 % -38.45 % -
EBIT Growth 88.22 % 13.52 % 732.59 % 55.17 %
Net Income Growth 57.98 % 37.46 % -193.2 % 36.68 %
Net Income 3 Yeari Growth Per Share 73.36 % 4.91 % -482.97 % 258.91 %
Net Income 5 Yeari Growth Per Share -0.47 % 122.63 % -58.26 % 741.83 %
Net Income 10 Yeari Growth Per Share -0.47 % 122.63 % -140.46 % 518.75 %
Operating Income Growth 119.63 % 10.52 % -169.98 % 127.38 %
Operating Cash Flow Growth (CFG) 24.13 % 9.57 % 86.41 % 52.71 %
Operating 3 Year CFG 87.89 % 71.6 % 211.36 % 118.72 %
Operating 5 Year CFG -143.24 % 196.04 % 357.22 % 269.64 %
Operating 10 Year CFG -143.24 % 196.04 % -62.49 % 1038.19 %
EPS Growth 64.2 % 33.33 % -190 % 32.81 %
EPS Diluted Growth 64.2 % 33.33 % -190 % 33.2 %
Book Value Per Share 62.45 % -1.63 % -30.36 % 12.91 %
Share Holder 3 Year Equity Growth Per Share 64.5 % -37.97 % -49.06 % 77.59 %
Share Holder 5 Year Equity Growth Per Share - -40.16 % -62.9 % 271.08 %
Share Holder 10 Year Equity Growth Per Share - -40.16 % -82.62 % 821.72 %
Dividend Per Share Growth - 49.01 % - -
Dividend 3 Year Growth Per Share - -49.79 % - -
Dividend 5 Year Growth Per Share - -49.97 % -100 % -
Dividend 10 Year Growth Per Share - -49.97 % -100 % -
Debt Growth 10.67 % 6.83 % -10.29 % 6.23 %
Free Cash Flow Growth 18.07 % 16.27 % 143.43 % 54.09 %
Updated On 31 Dec 2024 31 Dec 2024 31 Dec 2024 31 Dec 2024
Profitability
ALVOW ZTS TAK HLN TEVA NBIX
Gross Profit Margin TTM 53.68 % 70.63 % 52.77 % 61.81 % 49.6 % 98.37 %
Return on Assets TTM 4.55 % 17.49 % 0.98 % 4.78 % -0.39 % 10.03 %
Return on Equity TTM -20.57 % 53.56 % 1.95 % 9.4 % -2.58 % 15.82 %
Return on Capital Employed TTM 4.93 % 26.48 % 4.8 % 8.34 % 3.16 % 15.17 %
Net Income Per EBT TTM 188.9 % 79.59 % 72.4 % 76.52 % 222.54 % 68.09 %
EBT Per Ebit TTM 61.16 % 94.2 % 33.29 % 88.09 % -7.94 % 114.25 %
EBIT Per Revenue TTM 9.79 % 37.63 % 12.68 % 20.49 % 5.38 % 20.51 %
Cash Flow To Debt Ratio TTM -3.36 % 1429.41 % 22.35 % 12.02 % 7.93 % 148.65 %
Receivables Turnover TTM 3.1 6.1 6.59 5.14 4.67 3.69
Payables Turnover TTM 3.08 6.73 5.02 1.18 3.35 0.37
Inventory Turnover TTM 1.67 1.12 1.71 3.72 2.4 0.63
Fixed Asset Turnover TTM 126.98 % 241.44 % 229.02 % 589.57 % 321.73 % 473.81 %
Asset Turnover TTM 40.21 % 61.99 % 31.99 % 34.62 % 41.43 % 62.89 %
Operating Cash Flow Per Share TTM -0.15 6.58 643.53 0.11 1.21 6.41
Free Cash Flow Per Share TTM -0.5 5.06 521.29 0.1 0.78 5.97
Cash Per Share TTM 53.85 % 470.54 % 22368.59 % 7.46 % 188.4 % 1121.53 %
Operating Cash Flow Sales Ratio TTM -7.6 % 31.03 % 22.48 % 9.32 % 8.36 % 23.74 %
Free Cash Flow Operating Cash Flow Ratio TTM 328.6 % 76.82 % 81.01 % 90.65 % 64.03 % 93.14 %
Cash Flow Coverage Ratios TTM -3.36 % 1429.41 % 22.35 % 12.02 % 7.93 % 148.65 %
Price To Free Cash Flows Ratio TTM -12.39 23.35 8.68 34.34 39.25 25.82
Price To Operating Cash Flows Ratio TTM -36.75 18.02 6.98 31.66 25.12 24.04
Price Cash Flow Ratio TTM -36.75 18.02 6.98 31.66 25.12 24.04
Income Statement (TTM)
ALVOW ZTS TAK HLN TEVA NBIX
Revenue $0.49B $9.26B $4581.55B $11.23B $16.54B $2.36B
Gross Profit $0.3B $6.4B $3001.33B $6.95B $8.06B $2.32B
Gross Profit Ratio 62.16% 69.1% 65.51% 61.85% 48.74% 98.56%
EBITDA $-0.03B $3.87B $1210.51B $2.51B $4.43B $0.64B
Net Income $-0.23B $2.49B $107.93B $1.44B $-1.64B $0.34B
EPS Diluted -0.87 5.47 33.62 0.32 -1.45 3.29
Balance Sheet (MRQ)
ALVOW ZTS TAK HLN TEVA NBIX
Long Term Debt $1.15B $5.39B $3966.33B $8.62B $16.3B $0.46B
Total Liabilities $1.63B $9.47B $7312.37B $18.09B $33.61B $1.13B
Total Equity $-0.41B $4.77B $6935.98B $16.22B $5.72B $2.59B
Total Investments $0.02B $0.03B $382.4B $0.14B $0B $1.71B
Total Debt $1.19B $6.74B $4515.27B $10.1B $18.08B $0.46B
Total Assets $1.22B $14.24B $14248.34B $34.32B $39.33B $3.72B
Cash Flow Statement (TTM)
ALVOW ZTS TAK HLN TEVA NBIX
Net Income $-0.23B $2.5B $107.93B $1.44B $-1.65B $0.34B
Inventory $-0.05B $-0.04B $-34.97B $0.22B $0B $-0.02B
Dividends Paid $0B $-0.79B $-302.5B $-0.57B $0B $0B
Operating Cash Flow $-0.24B $2.95B $1057.18B $2.3B $2.55B $0.6B
Capital Expenditure $-0.06B $-0.66B $-200.8B $-0.25B $-0.5B $-0.04B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 5.57
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 0.735
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 4.995
AMPH Amphastar Pharmaceuticals, Inc. 26.08
AMRX Amneal Pharmaceuticals, Inc. 12.34
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 82.41
APUS Apimeds Pharmaceuticals US, Inc 2.02
AQST Aquestive Therapeutics, Inc. 5.63
ASRT Assertio Holdings, Inc. 0.7342
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 21.415
AYTU Aytu BioPharma, Inc. 2.6
Unlock